开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=)]

2022-08-02 ms6000001160390657

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：lncRNA
经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊

148 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=)]

2023-10-26 ms4000001583479348 来自北京

终于接收啦历经四个月。希望杂志越来越好吧。

99 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=)]

2024-01-21 ms9000001581615796 来自江苏省

审稿速度:2.0 | 投稿命中率:25.0
经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修

114 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=)]

2024-03-10 1811e984f8m 来自安徽省

审稿速度:2.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤;肿瘤化疗
经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。

163 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=)]

2024-07-03 ms6000000084807408 来自甘肃省

偏重的研究方向：肿瘤神经生物学
经验分享：7.1投了一篇综述，在这里记录一下投稿过程

71 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=)]

2024-03-19 ms7000000762441132 来自河南省

审稿速度:3.0
偏重的研究方向：cancer
经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers.

86 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=)]

2023-11-12 wym0577 来自浙江省

审稿速度:3.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤
经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？

0 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=)]

2024-01-10 1464d723m79暂无昵称来自广东省

Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？

107 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=)]

2024-04-22 a201061519 来自河南省

偏重的研究方向：肿瘤
经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？

80 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：lncRNA 经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2213026, encodeId=f0c5221302650, content=偏重的研究方向：肿瘤神经生物学 经验分享：7.1投了一篇综述，在这里记录一下投稿过程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45c89357763, createdName=ms6000000084807408, createdTime=Wed Jul 03 15:38:45 CST 2024, time=2024-07-03, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=)]

2021-07-27 Medicalresearch

under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢

155 8

展开8条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务